Suicide gene therapy for graft-versus-host disease

Immunotherapy
Anna-Maria GeorgoudakiEvren Alici

Abstract

In allogeneic hematopoietic stem cell transplantation, donor-derived T cells are key players for early immune reconstitution and efficient engraftment, as well as the graft-versus-leukemia and graft-versus-infection effects. However, a severe and quite common life-threatening complication is the development of graft-versus-host disease, during which the alloreactive donor T cells attack the host. Controlling graft-versus-host disease while preserving the benefits of graft-versus-leukemia still constitutes a challenge. A promising approach for the control of graft-versus-host disease is suicide gene therapy, which involves the ex vivo genetic modification of donor T cells with a suicide gene that allows for the selective elimination of the cells in vivo if graft-versus-host disease occurs. This article presents an overview of such approaches with special reference to lessons learned from previous clinical experiences, as well as a discussion of critical factors in suicide gene therapy.

References

May 10, 1979·The New England Journal of Medicine·P L WeidenR Storb
May 1, 1991·Antimicrobial Agents and Chemotherapy·D R AverettT A Krenitsky
Jan 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·C A MullenR M Blaese
Mar 7, 1991·The New England Journal of Medicine·J L Ferrara, H J Deeg
Feb 22, 1990·The New England Journal of Medicine·A M KrenskyP Parham
Apr 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·G P NolanL A Herzenberg
Sep 19, 1980·Science·R C Mulligan, P Berg
Aug 15, 1995·Proceedings of the National Academy of Sciences of the United States of America·B A BunnellR A Morgan
Jan 13, 1994·The New England Journal of Medicine·D L PorterJ H Antin
Jun 15, 1993·Cancer·Z B Kramer, B D Smith
Mar 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B M BärT De Witte
Apr 1, 1996·Hematology and Cell Therapy·P TiberghienP Hervé
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R H CollinsJ Nemunaitis
Apr 1, 1995·Chemistry & Biology·M L RodriguesB K Blackburn
Dec 13, 1997·Hematology and Cell Therapy·C Bonini, C Bordignon
Feb 4, 1999·Gene Therapy·M L CortésM Izquierdo
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L H SehnR J Soiffer
Apr 6, 1999·The Journal of Experimental Medicine·D ZengS Strober
Jun 3, 1999·The New England Journal of Medicine·E C GuinanJ G Gribben
Sep 24, 1999·Leukemia & Lymphoma·J L CohenD Klatzmann

❮ Previous
Next ❯

Citations

Jun 24, 2011·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Ellen PreussBoris Fehse
Jun 13, 2016·International Journal of Hematology·Evidio Domingo-Musibay, Masato Yamamoto

❮ Previous
Next ❯

Methods Mentioned

BETA
genetic modification

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.